Anna Vickers
About
Anna Vickers is a scholar working on Molecular Medicine, Pharmacology and Molecular Biology.
According to data from OpenAlex, Anna Vickers has authored 23 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Medicine, 15 papers in Pharmacology and 5 papers in Molecular Biology. Recurrent topics in Anna Vickers's work include Antibiotic Resistance in Bacteria (18 papers), Antibiotics Pharmacokinetics and Efficacy (15 papers) and Pharmaceutical and Antibiotic Environmental Impacts (4 papers). Anna Vickers is often cited by papers focused on Antibiotic Resistance in Bacteria (18 papers), Antibiotics Pharmacokinetics and Efficacy (15 papers) and Pharmaceutical and Antibiotic Environmental Impacts (4 papers). Anna Vickers collaborates with scholars based in United Kingdom, Switzerland and Jordan. Anna Vickers's co-authors include Shazad Mushtaq, David M. Livermore, Neil Woodford, Marina Warner, Alex J. O’Neill, David Litt, Shamez Ladhani, Andreas Haldimann, Sarah Collins and Mary Ramsay and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Emerging infectious diseases and Journal of Antimicrobial Chemotherapy.
In The Last Decade
Anna Vickers
23 papers receiving 685 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anna Vickers United Kingdom | 15 | 512 | 328 | 199 | 190 | 146 | 23 | 699 | ||
| Justin R. Lenhard United States | 16 | 527 1.0× | 365 1.1× | 174 0.9× | 130 0.7× | 172 1.2× | 29 | 735 | ||
| Patricia N. Holden United States | 16 | 485 0.9× | 386 1.2× | 199 1.0× | 103 0.5× | 151 1.0× | 35 | 739 | ||
| Sunil Maharjan United Kingdom | 9 | 551 1.1× | 316 1.0× | 167 0.8× | 135 0.7× | 83 0.6× | 14 | 643 | ||
| Eliana S. Armstrong United States | 12 | 509 1.0× | 292 0.9× | 160 0.8× | 85 0.4× | 238 1.6× | 17 | 722 | ||
| Anima Poudyal Australia | 7 | 530 1.0× | 329 1.0× | 173 0.9× | 76 0.4× | 131 0.9× | 10 | 634 | ||
| Franil Tailor Canada | 6 | 487 1.0× | 194 0.6× | 217 1.1× | 163 0.9× | 91 0.6× | 9 | 638 | ||
| Laura J. Rojas United States | 16 | 746 1.5× | 301 0.9× | 189 0.9× | 186 1.0× | 162 1.1× | 48 | 893 | ||
| Lauro Vieira Perdigão Neto Brazil | 15 | 396 0.8× | 228 0.7× | 214 1.1× | 93 0.5× | 89 0.6× | 56 | 610 | ||
| Naoki Kohira Japan | 8 | 681 1.3× | 475 1.4× | 167 0.8× | 188 1.0× | 199 1.4× | 12 | 830 | ||
| Alina Iovleva United States | 13 | 735 1.4× | 291 0.9× | 182 0.9× | 189 1.0× | 149 1.0× | 26 | 876 |
Countries citing papers authored by Anna Vickers
Since
Specialization
Citations
This map shows the geographic impact of Anna Vickers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Vickers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Vickers more than expected).
Fields of papers citing papers by Anna Vickers
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anna Vickers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Vickers. The network helps show where Anna Vickers may publish in the future.
Co-authorship network of co-authors of Anna Vickers
This figure shows the co-authorship network connecting the top 25 collaborators of Anna Vickers. A scholar is included among the top collaborators of Anna Vickers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Vickers. Anna Vickers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mushtaq, Shazad, et al.. (2024). Frequencies and mechanisms of mutational resistance to ceftibuten/avibactam in Enterobacterales. Journal of Antimicrobial Chemotherapy. 80(3). 645–656.
2.
Mushtaq, Shazad, Anna Vickers, Neil Woodford, & David M. Livermore. (2024). Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance. International Journal of Antimicrobial Agents. 63(3). 107081–107081.
3.
Livermore, David M., Shazad Mushtaq, Anna Vickers, & Neil Woodford. (2023). Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli. International Journal of Antimicrobial Agents. 61(5). 106776–106776.
4.
Mushtaq, Shazad, et al.. (2022). Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution. Journal of Antimicrobial Chemotherapy. 77(7). 1916–1922.
5.
Mushtaq, Shazad, et al.. (2021). Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. Journal of Antimicrobial Chemotherapy. 76(6). 1511–1522.
6.
Mushtaq, Shazad, Anna Vickers, Nicholas Ellaby, Neil Woodford, & David M. Livermore. (2021). Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales. Journal of Antimicrobial Chemotherapy. 77(1). 98–111.
7.
Mushtaq, Shazad, et al.. (2021). Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria. International Journal of Antimicrobial Agents. 57(5). 106318–106318.
8.
Mushtaq, Shazad, Anna Vickers, Michel Doumith, et al.. (2020). Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. 76(1). 160–170.
9.
Mushtaq, Shazad, Danièle Meunier, Anna Vickers, Neil Woodford, & David M. Livermore. (2020). Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. Journal of Antimicrobial Chemotherapy. 76(2). 434–442.
10.
Mushtaq, Shazad, et al.. (2020). In-vitro activity of cefiderocol against multidrug-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii isolates from the UK. Access Microbiology. 2(2).
11.
Vickers, Anna, Shazad Mushtaq, Neil Woodford, Michel Doumith, & David M. Livermore. (2018). Activity of RX-04 Pyrrolocytosine Protein Synthesis Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy. 62(8).
12.
Livermore, David M., Shazad Mushtaq, Marina Warner, Anna Vickers, & Neil Woodford. (2017). In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. 72(5). 1373–1385.
13.
Mushtaq, Shazad, Anna Vickers, Neil Woodford, & David M. Livermore. (2017). WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases. Journal of Antimicrobial Chemotherapy. 72(6). 1688–1695.
14.
Vickers, Anna, et al.. (2017). 263EMF Epidemiology of Lumbar Punctures in Hospitalized Patients in United States. Annals of Emergency Medicine. 70(4). S104–S104.
15.
Collins, Sarah, Anna Vickers, Shamez Ladhani, et al.. (2015). Clinical and Molecular Epidemiology of Childhood Invasive Nontypeable Haemophilus influenzae Disease in England and Wales. The Pediatric Infectious Disease Journal. 35(3). e76–e84.
16.
Aqel, Amin A., Hamed Alzoubi, Anna Vickers, Bruno Pichon, & Angela Kearns. (2014). Molecular epidemiology of nasal isolates of methicillin-resistant Staphylococcus aureus from Jordan. Journal of Infection and Public Health. 8(1). 90–97.
17.
Ladhani, Shamez, Sarah Collins, Anna Vickers, et al.. (2012). InvasiveHaemophilus influenzaeSerotype e and f Disease, England and Wales. Emerging infectious diseases. 18(5). 725–732.
18.
Vickers, Anna, et al.. (2009). Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. Journal of Antimicrobial Chemotherapy. 63(6). 1112–1117.
19.
Vickers, Anna, Alex J. O’Neill, & I. Chopra. (2007). Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies. Journal of Antimicrobial Chemotherapy. 60(2). 269–273.
20.
Vickers, Anna, Ian Chopra, & Alex J. O’Neill. (2007). Intrinsic Novobiocin Resistance in Staphylococcus saprophyticus. Antimicrobial Agents and Chemotherapy. 51(12). 4484–4485.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Justin R. Lenhard Breakdown of academic impact, for papers by Patricia N. Holden Breakdown of academic impact, for papers by Sunil Maharjan Breakdown of academic impact, for papers by Eliana S. Armstrong Breakdown of academic impact, for papers by Anima Poudyal Breakdown of academic impact, for papers by Franil Tailor Breakdown of academic impact, for papers by Laura J. Rojas Breakdown of academic impact, for papers by Lauro Vieira Perdigão Neto Breakdown of academic impact, for papers by Naoki Kohira Breakdown of academic impact, for papers by Alina Iovleva